Generic Name and Formulations:
Buspirone HCl 5mg, 10mg, 15mg+, 30mg+; scored (+bi/trisected) tabs.
Various generic manufacturers
Indications for Buspirone:
Take consistently with regard to food. Initially 7.5mg twice daily, may increase by 5mg/day every 2–3 days. Usual range: 20–30mg/day; max 60mg/day.
<6yrs: not recommended. 6–17yrs: doses of 7.5–30mg twice daily have been used.
Severe renal or hepatic impairment: not recommended. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.
Hypertensive crisis with MAOIs: see Contraindications. Avoid alcohol, large amounts of grapefruit juice. Caution with other CNS drugs. May potentiate haloperidol, diazepam, nefazodone. Potentiated by nefazodone, verapamil, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, other CYP3A4 inhibitors (use lower initial dose). Antagonized by rifampin, dexamethasone, phenytoin, phenobarbital, carbamazepine, other CYP3A4 inducers.
Dizziness, GI upset, headache, nervousness, CNS or emotional effects, nonspecific chest pain, tinnitus, dream disturbances.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|